drugset / Trial / NCT02099188
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Phase 2
Unknown
27 enrolled
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Regione Lombardia · collab
NaSingle-groupOpen-labelTreatment
Summary
Sinonasal tumors are rare diseases, as they account for the 0.2 % - 0.8 % of all tumors. For patients with inoperable tumors, the prognosis is poor and the current therapy is a combined-modality treatment that is both more effective and associated with less morbidity. This study proposes innovative integration of multiple modality of treatment modulated by histology, molecular profile and response to induction CT.
Timeline
- Start
- 2013-11
- Primary completion
- 2020-06
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 33 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 3000 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 250 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 800 mg/m2 | Intravenous |